NY-CITCO-GROUP-OF-COMP
30.5.2019 18:05:10 CEST | Business Wire | Press release
The Citco Group of Companies, (“Citco”), a leading provider of asset servicing solutions to the global alternative investment industry, today announced a product partnership with S3 Partners, a leading fintech innovator and data analytics firm, and the integration of its BLACKLIGHT Treasury Management solution.
S3 Partners’ real-time, independent financing data prices opaque borrow and loan markets and redefines short interest, crowding and previously stale indicators for which the industry has had no centralized source. BLACKLIGHT leverages these analytics along with leading technology for better outcomes in investment process, risk management, and counterparty relationships.
The agreement between Citco and S3 allows Citco clients to get the benefit of BLACKLIGHT’s Financing Trade Cost Analytics (FinTCA) tools to maximize trade, margin and collateral exposures and efficiencies. The platform will be rolled out via Citco’s Æxeo Treasury platform.
“Our focus at Citco has always been to provide our clients with the best technologies and services to make their lives easier. This is why we have decided to integrate S3’s market-standard BLACKLIGHT suite of data and technology,” said Albert Bauer, Managing Director at Citco Fund Services (USA) Inc. “Integrating BLACKLIGHT into our existing Citco framework enables us to provide S3’s efficient insights to best execution, cost of margin and working capital and to monitor liquidity alongside our new Æxeo Treasury platform. Our clients have asked for these nuanced analytics which we can now offer via BLACKLIGHT with single-sign-on access and virtually no operational friction.”
“We are thrilled that Citco has chosen to partner with us and recognizes the value of our broker-neutral solutions,” said Bob Sloan, Founder of S3 Partners. “The Citco-S3 alliance, along with our distribution via Bloomberg, Nasdaq and Reuters, expands the reach of our technology and data to every player type and client segment.”
About Citco Group of Companies
The Citco Group of Companies (Citco) is a leading provider of asset servicing solutions to the global alternative investment industry. With over $1 trillion in assets under administration and 6,500 staff deployed across 40 countries, Citco’s unique culture of innovation and client-driven solutions has provided Citco’s clients with a trusted partner for more than four decades. Having grown organically into one of the largest asset servicers in the industry, Citco’s Fund Services division offers a full suite of middle office and back office services including, treasury and loan handling, daily NAV calculations and investor services, corporate and legal services, regulatory and risk reporting as well as tax and financial reporting services. Investing heavily in innovation and technology whilst further developing its current suite of client friendly solutions, Citco will continue as a flagbearer for the asset servicing industry. For more information, go to www.Citco.com .
About S3 Partners
Founded in 2003, S3 Partners is a financial technology and data company. Clients use our technology and data for better outcomes in their investment process, risk management, counterparty relationships, and investor relations. Like any resource, the integrity and purity of data is defined by how it’s sourced, how and why it’s filtered, who can access it, and how it’s interpreted. Data is only potential until you find a way to refine it. Refining data potential into financial power is S3’s business. Our suite of tools arms you to not just access data but to wield it; cut through marketplace opacity and see with clarity where opportunity lies for your business, portfolio, and the entire market. S3’s comprehensive data integrity powers your market perception and business intelligence so you can act with agility, on your own terms. For more information about S3 Partners, please visit s3partners.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190530005653/en/
Contact:
For Citco New York Hannah Beard | +1 646 274 1421 London Aryna Kastavetskaya | +44 20 3040 0871 citco@peregrinecommunications.com For S3 Partners ASC Advisors Steve Bruce / Taylor Ingraham sbruce@ascadvisors.com / tingraham@ascadvisors.com 203-992-1230
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom